French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting
Observational Study
Pancreatic Cancer Resectable
Pancreatic Ductal Adenocarcinoma
Minimal Residual Disease
Liquid Biopsy
ctDNA
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 37 (estimated)
- Sponsor
- University Hospital, Montpellier · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.
Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.
Specifically, the investigators want to…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
* Age 18 years or older.
* Scheduled for curative intent surgical resection.
Exclusion Criteria:
* Hereditary pancreatic cancer.
* Verified distant metastases.
* Patients who are unlikely to comply wit…
Contacts